Canada Pension Plan Investment Board Purchases Shares of 10,218,400 Sana Biotechnology, Inc. $SANA

Key Points

• Canada Pension Plan Investment Board acquired 10.2 million Sana Biotechnology shares worth approximately $35.7 million, giving it a 3.41% stake. Institutional investors collectively own 88.23% of the company.
• Analyst sentiment is broadly positive, with Sana receiving a consensus “Moderate Buy” rating and a $9.33 target price, although ratings range from “Strong Buy” to “Sell.”
• Sana’s stock opened at $4.09, while the clinical-stage biotech reported a quarterly loss of $0.13 per share—better than the expected $0.15 loss—and analysts project a full-year loss of $0.72 per share.

Canada Pension Plan Investment Board purchased a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,218,400 shares of the company's stock, valued at approximately $35,662,000. Canada Pension Plan Investment Board owned about 3.41% of Sana Biotechnology as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Sana Biotechnology during the second quarter worth approximately $58,196,000. Alphabet Inc. purchased a new position in shares of Sana Biotechnology during the second quarter worth approximately $9,816,000. Bank of America Corp DE grew its position in shares of Sana Biotechnology by 148.4% during the first quarter. Bank of America Corp DE now owns 2,946,861 shares of the company's stock worth $8,487,000 after acquiring an additional 1,760,610 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in shares of Sana Biotechnology in the 4th quarter valued at $6,834,000. Finally, Vanguard Group Inc. raised its position in Sana Biotechnology by 19.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company's stock valued at $32,408,000 after purchasing an additional 1,517,474 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on SANA shares. Wall Street Zen downgraded shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Bank of America reduced their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 14th. Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They set a "buy" rating and a $16.00 price target on the stock. Weiss Ratings upgraded Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 23rd. Finally, TD Cowen raised Sana Biotechnology to a "strong-buy" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Sana Biotechnology presently has an average rating of "Moderate Buy" and a consensus target price of $9.33.

Sana Biotechnology Stock Performance

SANA stock opened at $4.09 on Friday. The stock has a market capitalization of $1.22 billion, a PE ratio of -5.38 and a beta of 2.16. The company has a fifty day moving average of $3.56 and a 200-day moving average of $3.41. Sana Biotechnology, Inc. has a one year low of $2.61 and a one year high of $6.55.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. Equities analysts forecast that Sana Biotechnology, Inc. will post -0.72 earnings per share for the current fiscal year.

Sana Biotechnology Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

Want to see what other hedge funds are holding SANA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source